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MarkusHöltje,10 Kristina Dietert,11,12 Laura Stöffler,1,3 Niels vonWardenburg,1,3 Scott vanHoof,1,2,3Marie A. Homeyer,1,3,5
Julius Hoffmann,1,3 Azza Abdelgawad,9 Achim D. Gruber,11 Luca D. Bertzbach,9 Daria Vladimirova,9 Lucie Y. Li,2,10
Paula Charlotte Barthel,10 Karl Skriner,13 Andreas C. Hocke,14 Stefan Hippenstiel,14
(Author list continued on next page)
1German Center for Neurodegenerative Diseases (DZNE) Berlin, 10117 Berlin, Germany
2Helmholtz Innovation Lab BaoBab (Brain Antibody-omics and B-cell Lab), 10117 Berlin, Germany
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Berlin, Humboldt-Universität Berlin, and Berlin Institute of Health, 10117 Berlin, Germany
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(Affiliations continued on next page)SUMMARYThe emergence of SARS-CoV-2 led to pandemic spread of coronavirus disease 2019 (COVID-19), manifesting
with respiratory symptoms and multi-organ dysfunction. Detailed characterization of virus-neutralizing anti-
bodies and target epitopes is needed to understand COVID-19 pathophysiology and guide immunization
strategies. Among 598 human monoclonal antibodies (mAbs) from 10 COVID-19 patients, we identified 40
strongly neutralizing mAbs. The most potent mAb, CV07-209, neutralized authentic SARS-CoV-2 with an
IC50 value of 3.1 ng/mL. Crystal structures of two mAbs in complex with the SARS-CoV-2 receptor-binding
domain at 2.55 and 2.70 Å revealed a direct block of ACE2 attachment. Interestingly, some of the near-germ-
line SARS-CoV-2-neutralizing mAbs reacted with mammalian self-antigens. Prophylactic and therapeutic
application of CV07-209 protected hamsters from SARS-CoV-2 infection, weight loss, and lung pathology.
Our results show that non-self-reactive virus-neutralizing mAbs elicited during SARS-CoV-2 infection are a
promising therapeutic strategy.INTRODUCTION
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
started emerging in humans in late 2019 and rapidly became a
pandemic with millions of cases worldwide. SARS-CoV-2 infec-
tion causes coronavirus disease 2019 (COVID-19) with severe
respiratory symptoms, pathological inflammation, and multi-or-
gan dysfunction, including acute respiratory distress syndrome,
cardiovascular events, coagulopathies, and neurological symp-
toms (Helms et al., 2020; Zhou et al., 2020; Zhu et al., 2020).
Some aspects of the diverse clinical manifestations may result
from a hyperinflammatory response, as suggested by reduced
mortality in hospitalized COVID-19 patients under dexametha-
sone therapy (Horby et al., 2020).1058 Cell 183, 1058–1069, November 12, 2020 ª 2020 The Authors.
This is an open access article under the CC BY license (http://creativeUnderstanding the immune response to SARS-CoV-2 is of
utmost importance. Multiple recombinant SARS-CoV-2 mono-
clonal antibodies (mAbs) from convalescent patients have
been reported (Brouwer et al., 2020; Cao et al., 2020; Ju et al.,
2020; Kreer et al., 2020; Robbiani et al., 2020; Rogers et al.,
2020; Wec et al., 2020). mAbs targeting the receptor-binding
domain (RBD) of the viral spike protein S1 can compete with
its binding to human angiotensin-converting enzyme 2 (ACE2)
and prevent virus entry and subsequent replication (Cao et al.,
2020; Ju et al., 2020; Walls et al., 2020). Potent virus-neutralizing
mAbs that were isolated from diverse variable immunoglobulin
(Ig) genes typically carry low levels of somatic hypermutations
(SHMs). Several of these neutralizing mAbs selected for in vitro
efficacy showed prophylactic or therapeutic potential in animalPublished by Elsevier Inc.
commons.org/licenses/by/4.0/).
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OPEN ACCESSArticlemodels (Cao et al., 2020; Liu et al., 2020; Rogers et al., 2020;
Zost et al., 2020). The low number of SHMs suggests limited af-
finity maturation in germinal centers compatible with an acute
infection. Near-germline mAbs usually constitute the first line
of defense against pathogens but carry the risk of self-reactivity
to autoantigens (Lerner, 2016; Liao et al., 2011; Zhou et al.,
2007). Although critical for therapeutic use in humans, the poten-
tial tissue reactivity of near-germline SARS-CoV-2 antibodies
has so far not been examined.
Here we systematically selected 18 strongly neutralizing
mAbs of 598 antibodies from 10 COVID-19 patients by char-
acterization of their biophysical properties, authentic SARS-
CoV-2 neutralization, and exclusion of off-target binding to
murine tissue. Additionally, we solved two crystal structures
of neutralizing mAbs in complex with the RBD, showing anti-
body engagement with the ACE2 binding site from different
approach angles. Finally, we selected mAb CV07-209 for
in vivo evaluation because of its in vitro efficacy and absence
of tissue reactivity. Systemic application of CV07-209 in a
hamster model of SARS-CoV-2 infection led to a profound
reduction of clinical, paraclinical, and histopathological
COVID-19 pathology, reflecting its potential for translational
application in patients with COVID-19.
RESULTS
Antibody Repertoire Analysis of COVID-19 Patients
Wefirst characterized the B cell response in COVID-19 using sin-
gle-cell Ig gene sequencing of humanmAbs (Figure 1A). From 10COVID-19 patients with serum antibodies to the S1 subunit of
the SARS-CoV-2 spike protein (Figure S1A; Table S1), we iso-
lated two populations of single cells fromperipheral bloodmono-
nuclear cells with fluorescence-activated cell sorting (FACS):
CD19+CD27+CD38+ antibody-secreting cells (ASCs) reflecting
the overall humoral immune response and SARS-CoV-2-S1-
labeled CD19+CD27+ memory B cells (S1-MBCs) for character-
ization of antigen-specific responses (Figures S1B and S1C). We
obtained 598 functional paired heavy- and light-chain Ig se-
quences (Table S2). Of 432 recombinantly expressed mAbs,
122 were reactive to SARS-CoV-2-S1 (S1+) with a frequency of
0.0%–18.2% (median, 7.1%) within ASCs and 16.7%–84.1%
(median, 67.1%) within S1-MBCs (Figures 1B and 1C). Binding
to S1 did not depend on affinity maturation, as measured by
the number of SHMs (Figure 1D). Compared with mAbs not reac-
tive to SARS-CoV-2-S1, S1+ mAbs had fewer SHMs but equal
lengths of their light- and heavy-chain complementarity-deter-
mining region 3 (CDR3) (Figures S1D–S1F). Within the ASC and
S1-MBC population, 45.0% and 90.2% of S1+ mAbs, respec-
tively, bound the RBD (Figure S1G).
S1+mAbswere enriched in certain Ig genes, including variable
heavy (VH)1-2, VH3-53, VH3-66, variable kappa (VK)1-33, and
variable lambda (VL)2-14 (Figure S2). We identified clonally
related antibody clones within patients and public and shared
S1+ clonotypes from multiple patients (Figures S3A and S3B).
Some public or shared clonotypes had been reported previously,
such as IGHV3-53 and IGHV3-66 (Figure S3D; Cao et al., 2020;
Yuan et al., 2020a), whereas others were newly identified, such
as IGHV3-11 (Figure S3C).Cell 183, 1058–1069, November 12, 2020 1059
Figure 1. Identification and Characterization of Potent SARS-CoV-2-Neutralizing mAbs
(A) Diagram depicting the strategy for isolation of 18 potently neutralizing mAbs (top 18).
(B) Normalized binding to S1 of SARS-CoV-2 for mAbs isolated from ASCs (inverted triangles; blue, S1-binding; gray, not S1-binding). OD, optical density
in ELISA.
(C) Normalized binding to S1 of SARS-CoV-2 for mAbs isolated from S1-stained MBCs (triangles; colors as in B).
(D) S1-binding plotted against the number of somatic hypermutations (SHMs) for all S1-reactive mAbs.
(E) Concentration-dependent binding of the top 18 SARS-CoV-2 mAbs to the RBD of S1 (mean ± SD from two wells of one experiment).
(F) Concentration-dependent neutralization of authentic SARS-CoV-2 plaque formation by the top 18 mAbs (mean ± SD from two independent measurements).
(G) Apparent affinities of mAbs to RBDs (KD determined by surface plasmon resonance) plotted against IC50 of authentic SARS-CoV-2 neutralization.
See also Figures S1, S2, S3, S4, and S5 and Tables S1, S2, and S3.
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OPEN ACCESS ArticleIdentification and Characterization of Potent SARS-
CoV-2-Neutralizing mAbs
We next determined mAbs with the highest capacity to neutralize
SARS-CoV-2 in plaque reduction neutralization tests (PRNTs) us-
ing an authentic virus (Munich isolate 984) (Wölfel et al., 2020). Of
87mAbs strongly binding to the RBD, 40 showed virus neutraliza-
tion with a half-maximal inhibitory concentration (IC50) of 250 ng/
mLor less andwere consideredneutralizing antibodies (Figure 1A;
Table S2), of which 18 (top 18) were selected for further character-
ization (Table S3). The antibodies bound to the RBD with a half-
maximal effective concentration (EC50) of 3.8–14.2 ng/mL (Fig-
ure 1E) and an equilibrium dissociation constant (KD) of 6.0 pM
to 1.1 nM (Figure S4; Table S3), neutralizing SARS-CoV-2 with
an IC50 value of 3.1–172 ng/mL (Figure 1F; Table S3). The antibody
with the highest apparent affinity, CV07-209, was also the stron-
gest neutralizer (Figure 1G). We hypothesized that the differences
in neutralizing capacity relate to different interactions with the
ACE2 binding site. Indeed, the strongest neutralizing mAbs,
CV07-209 and CV07-250, reduced ACE2 binding to the RBD to
12.4% and 58.3%, respectively. Other top 18 mAbs, including
CV07-270, interfered only weakly with ACE2 binding (Figure S5A).
The spike proteins of SARS-CoV-2 and SARS-CoV sharemore
than 70% amino acid sequence identity, whereas sequence1060 Cell 183, 1058–1069, November 12, 2020identity between SARS-CoV-2 and MERS-CoV and other
endemic coronaviruses is significantly lower (Barnes et al.,
2020). To analyze potential cross-reactivity of mAbs to other co-
ronaviruses, we tested for binding of the top 18mAbs to the RBD
of SARS-CoV, MERS-CoV, and the human endemic coronavi-
ruses 229E, NL63, HKU1, and OC43. CV38-142 detected the
RBDs of SARS-CoV-2 and SARS-CoV, whereas no other mAb
was cross-reactive to additional coronaviruses (Figures S5C
and S5D). To further characterize the epitope of neutralizing
mAbs, we performed ELISA-based epitope binning experiments
using biotinylated antibodies. Co-application of paired mAbs
showed competition of most neutralizing antibodies for RBD
binding (Figure S5B). As an exception, the SARS-CoV cross-
reactive CV38-142 bound the RBD irrespective of the presence
of other mAbs, suggesting an independent and conserved target
epitope (Figure S5B).
Near-Germline SARS-CoV-2 Neutralizing Antibodies
Can Bind to Murine Tissue
Many SARS-CoV-2-neutralizing mAbs carry few SHMs or are in
germline configuration (Figure 1D; Ju et al., 2020; Kreer et al.,
2020). Antibodies close to the germline might be reactive to
more than one target (Zhou et al., 2007). Prompted by the
Figure 2. SARS-CoV-2-Neutralizing Anti-
bodies Can Bind to Murine Tissue
Immunofluorescence staining of SARS-CoV-2
mAbs (green) on murine organ sections showed
specific binding to distinct anatomical struc-
tures.
(A) Staining of hippocampal neuropil with CV07-200
(cell nuclei depicted in blue).
(B) Staining of bronchial walls with CV07-222.
(C) Staining of vascular walls with CV07-255.
(D) Staining of intestinal walls with CV07-270.
Smooth muscle tissue in (B)–(D) was co-stained
with a commercial smooth muscle actin anti-
body (red). Scale bars, 100 mm. See also
Table S3.
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OPEN ACCESSArticleabundance of near-germline SARS-CoV-2 antibodies and to
exclude potential side effects of mAb treatment, we next
analyzed whether SARS-CoV-2 antibodies can bind to self-
antigens.
We tested binding of S1 mAbs to unfixed murine tissues. Sur-
prisingly, four of the top 18 potent SARS-CoV-2-neutralizing
mAbs showed anatomically distinct tissue reactivities (Figure 2;
Table S3). CV07-200 intensively stained brain sections in the hip-
pocampal formation, olfactory bulb, cerebral cortex, and basal
ganglia (Figure 2A). CV07-222 also bound to brain tissue as
well as to smooth muscle (Figure 2B). CV07-255 and CV07-
270 were reactive to smooth muscle from sections of lung, heart,
kidney, and colon but not liver (Figures 2C and 2D; Table S3).
None of the top 18 mAbs bound to HEp-2 cells, cardiolipin, or
beta-2 microglobulin as established polyreactivity-related anti-
gens (Jardine et al., 2016; Figure S5E).
Crystal Structures of Two mAbs Approaching the ACE2
Binding Site from Different Angles
Diffraction-quality crystals were obtained for the SARS-CoV-2
RBD complexed with two individual neutralizing mAbs, CV07-
250 and CV07-270, which have notable differences in the num-
ber of SHMs, extent of ACE2 competition, and binding to murine
tissue. CV07-250 (IC50 = 3.5 ng/mL) had 33 SHMs (17/16 on the
heavy and light chain, respectively) and strongly reduced ACE2
binding and showed no binding to murine tissue. In contrast,
CV07-270 (IC50 = 82.3 ng/mL) had only 2 SHMs (2/0), did not
reduce ACE2 binding in our assay, and showed binding to
smooth muscle tissue. Using X-ray crystallography, we deter-
mined the structures of CV07-250 and CV07-270 in complex
with the SARS-CoV-2 RBD to resolutions of 2.55 and 2.70 Å,
respectively (Figure 3; Tables S4 and S5).CeThe binding mode of CV07-250 to the
RBD is unusual in that it is dominated
by the light chain (Figures 3A and 3D),
whereas in CV07-270, the heavy chain
dominates, as found frequently in other
antibodies (Figures 3B and 3E). Upon
interaction with the RBD, CV07-250 has
a buried surface area (BSA) of 399 Å2
and 559 Å2 on the heavy and light chains,
respectively, compared with 714 Å2 and111 Å2 in CV07-270. CV07-250 uses CDR H1, H3, L1, and
L3 and framework region 3 (LFR3) for RBD interaction (Figures
3D and 4A–4C), whereas CV07-270 interacts with CDR H1,
H3, L1, and L2 (Figures 3E and 4D–4F).
The epitope of CV07-250 completely overlaps with the
ACE2 binding site with a similar angle of approach as ACE2
(Figures 3A, 3C, 4G, and 4I). In contrast, the CV07-270
epitope only partially overlaps with the ACE2 binding site,
and the antibody approaches the RBD from a different angle
compared with CV07-250 and ACE2 (Figures 3B, 3C, 4H,
and 4I), explaining differences in ACE2 competition. Although
CV07-250 and CV07-270 contact 25 epitope residues, only
seven residues are shared (G446/G447/E484/G485/Q493/
S494/Q498). Furthermore, CV07-270 binds to a similar
epitope as the SARS-CoV-2-neutralizing antibody P2B-2F6
(Ju et al., 2020) with a similar angle of approach (Figure S5F).
In fact, 18 of 20 residues in the P2B-2F6 epitope overlap with
the CV07-270 epitope, although CV07-270 and P2B-2F6 are
encoded by different germline genes for the heavy and light
chains. Thus, these two mAbs represent antibodies encoded
by different germline genes that bind to the same epitope in
the RBD with near-identical binding modes and approach an-
gles. This structural convergence is also encouraging for tar-
geting this highly immunogenic epitope for vaccine
development.
Interestingly, CV07-250 was isolated 19 days after symptom
onset but had already acquired 33 SHMs, the highest number
among all S1+ MBCs (Figure S1D). Some non-germline amino
acids are not directly involved in RBD binding, including all five
SHMs on CDR H2 (Figure S6). This observation suggests that
CV07-250 could have been initially affinity matured against a
different antigen.ll 183, 1058–1069, November 12, 2020 1061
Figure 3. Crystal Structures of mAbs in Com-
plex with the SARS-CoV-2 RBD
(A) CV07-250 (cyan) in complex with the RBD
(white).
(B) CV07-270 (pink) in complex with the RBD (white).
(C) Human ACE2 with the SARS-CoV-2 RBD (PDB:
6M0J; Lan et al., 2020).
(D and E) Epitopes of (D) CV07-250 and (E) CV07-
270. Epitope residues contacting the heavy chain
are shown in orange and those contacting the light
chain in yellow. CDR loops and the framework re-
gion that contact the RBD are labeled.
(F) ACE2-binding residues on the RBD (blue) in the
same view as in (D) and (E). The ACE2-interacting
region is shown in green within a semi-transparent
cartoon representation.
See also Figures S5 and S6 and Tables S4 and S5.
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Animal Model
Next we selectedmAbCV07-209 for evaluation of in vivo efficacy
based on its high capacity to neutralize SARS-CoV-2 and the
absence of reactivity to mammalian tissue. We used the hamster
model of COVID-19 because it is characterized by rapid weight
loss and severe lung pathology (Osterrieder et al., 2020). In this
experimental setup, hamsters were infected intranasally with
authentic SARS-CoV-2. Nine hamsters per group received a pro-
phylactic application of CV07-209 24 h before virus challenge or
a therapeutic application of CV07-209 or the control antibody
mGO53 2 h after virus challenge (Figure 5A).
Hamsters under control mAb treatment lost 5.5% ± 4.4%
(mean ± SD) of body weight, whereas those that received
mAb CV07-209 as a therapeutic or prophylactic single dose
gained 2.2% ± 3.4% or 4.8% ± 3.4% weight after 5 days
post-infection (dpi), respectively. Mean body weights gradually
converged in animals followed up until 13 dpi, reflecting recov-
ery of control-treated hamsters from SARS-CoV-2 infection
(Figure 5B).
To investigate the presence of SARS-CoV-2 in the lungs, we
measured functional SARS-CoV-2 particles from lung tissue ho-
mogenates. Plaque-forming units were below the detection
threshold for all animals in the prophylactic group and in 2 of 3
in the treatment group at 3 and 5 dpi (Figures 5C and 5D).
qPCRmeasurements of lung viral genomic RNA copies revealed
a 4–5 and 3–4 log reduction at both time points in the prophylac-
tic and therapeutic groups, indicating a drastic decrease in
SARS-CoV-2 particles in the lungs after CV07-209 application.
Reduced virus replication and cell infection was confirmed by
lowered detection of subgenomic viral RNA (Figures 5C and
5D). However, genomic and subgenomic RNA levels from nasal
washes and laryngeal swaps were similar between all groups,1062 Cell 183, 1058–1069, November 12, 2020indicating virus replication in the upper air-
ways (Figures 5C and 5D).
Additionally, we performed histopatho-
logical analyses of infected hamsters. As
expected, all lungs from control-treated
animals sacrificed at 3 dpi revealed typical
histopathological signs of necro-suppura-tive pneumonia with suppurative bronchitis, necrosis of bron-
chial epithelial cells, and endothelialitis (Figure 6A). At 5 dpi, con-
trol-treated animals showed marked bronchial hyperplasia,
severe interstitial pneumonia with marked type II alveolar epithe-
lial cell hyperplasia, and endothelialitis (Figure 6D). In contrast,
animals receiving prophylactic treatment with CV07-209 showed
no signs of pneumonia, bronchitis, necrosis of bronchial epithe-
lial cells, or endothelialitis at 3 dpi. Mild interstitial pneumonia
with mild type II alveolar epithelial cell hyperplasia became
apparent 5 dpi. Animals receiving therapeutic CV07-209 treat-
ment also showed a marked reduction in histopathological signs
of COVID-19 pathology, although, at both time points, one of
three animals showed mild bronchopulmonary pathology with
signs of interstitial pneumonia and endothelialitis. These qualita-
tive findings were mirrored in the reduction of bronchitis and
edema scores (Figures 6B and 6E; Table S6).
To confirm the absence of viral particles under CV07-209
treatment, we performed in situ hybridization of viral RNA at 3
dpi. No viral RNA was detectable in the prophylactic group,
whereas all animals in the control group and one in the therapeu-
tic group revealed intensive staining of viral RNA in proximity of
bronchial epithelial cells (Figure 6C). These findings show that
systemic application of the SARS-CoV-2-neutralizing mAb
CV07-209 protects hamsters from COVID-19 lung pathology
and weight loss in prophylactic and therapeutic settings.
DISCUSSION
Driven by the pandemic spread of COVID-19 in early 2020,
numerous groups have reported isolation, characterization,
structural analysis, and animal model application of SARS-
CoV-2-neutralizing mAbs (Barnes et al., 2020; Brouwer et al.,
2020; Cao et al., 2020; Ju et al., 2020; Kreer et al., 2020; Robbiani
Figure 4. Interactions and Angle of
Approach at the RBD-Antibody Interface
(A–C) Key interactions between CV07-250 (cyan)
and the RBD (white) are highlighted.
(A) CDR H3 of CV07-250 forms a hydrogen bond
network with RBD Y489 and N487.
(B) VH Y100b (CDR H3), VL F32 (CDR L1), and VL
Y91 (CDR L3) of CV07-250 form a hydrophobic
aromatic patch for interaction with RBD L455 and
F456.
(C) The side chain of VL S67 and backbone amide
of VL G68 from FR3 are engaged in a hydrogen
bond network with RBD G446 and Y449.
(D–F) Interactions between CV07-270 (cyan) and
the RBD (white).
(D) Residues in CDR H1 of CV07-270 participate in
an electrostatic and hydrogen bond network with
RBD R346 and K444.
(E) VHW100h and VHW100k on CDR H3 of CV07-
270 make p-p stacking interactions with Y449. VH
W100k is also stabilized by a p-p stacking inter-
action with VL Y49.
(F) VH R100 g on CDR H3 of CV07-270 forms an
electrostatic interaction with RBD E484 as well as
a p-cation interaction with RBD F490. Oxygen
atoms are shown in red and nitrogen atoms in
blue. Hydrogen bonds are represented by dashed
lines.
(G–I) Magnified views of the different RBD ridge
interactions with (G) CV07-250, (H) CV07-270, and
(I) ACE2 (PDB: 6M0J; Lan et al., 2020). The ACE2-
binding ridge in the RBD is represented by a
backbone ribbon trace in red.
See also Figures S5 and S6 and Tables S4 and S5.
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OPEN ACCESSArticleet al., 2020; Rogers et al., 2020; Wec et al., 2020). In many pla-
ces, our work confirms previous results, including observation
of a shared antibody response against the SARS-CoV-2 spike
protein, identification of ACE2 blocking as an important mecha-
nism of virus neutralization, isolation of high-affinity near-germ-
line antibodies, and in vivo efficacy of prophylactic mAb applica-
tion. Our results add several findings to the growing knowledge
about the humoral immune response in SARS-CoV-2 infection.
First, we provide two structures of neutralizingmAbs identified
in this study as binding to the RBD of SARS-CoV-2 at resolutions
of 2.55 and 2.70 Å, allowing detailed characterization of the
target epitopes and the SARS-CoV-2 neutralization mechanism
of these two mAbs. SARS-CoV-2 mAbs can compete with
ACE2 binding and exert neutralizing activity by inhibiting virus
particle binding to host cells (Barnes et al., 2020; Brouwer
et al., 2020; Cao et al., 2020; Ju et al., 2020; Kreer et al., 2020;
Robbiani et al., 2020; Rogers et al., 2020; Wec et al., 2020), a
key mechanism identified previously in SARS-CoV-neutralizing
antibodies (Prabakaran et al., 2006; ter Meulen et al., 2006). Ste-
ric hindrance of mAbs blocking ACE2 binding to the RBD pro-
vides onemechanistic explanation of virus neutralization (Barnes
et al., 2020; Cao et al., 2020; Wu et al., 2020). CV07-250 clearly
belongs to this category of antibodies because its epitope lies
within the ACE2 binding site, and it approaches the RBD from
a similar angle as ACE2. In contrast, the epitope of CV07-270only partially overlaps with the ACE2 binding site and ap-
proaches the RBD ridge from a different angle. In line with these
findings, competition of CV07-270 with ACE2 binding, as de-
tected by ELISA, was very weak; therefore, its mechanism of vi-
rus neutralization remains elusive. Of note, there have been re-
ports of neutralizing antibodies targeting epitopes distant to
the ACE2 binding site (Chi et al., 2020). Future research will
need to clarify whether additional mechanisms, like triggering
conformational changes in the spike protein upon antibody bind-
ing, contribute to virus neutralization, as reported for SARS-CoV
(Walls et al., 2019).
Second, the majority of our SARS-CoV-2 mAbs are close to
germline configuration, supporting previous studies (Kreer
et al., 2020; Robbiani et al., 2020). Binding of some antibodies
to HEp-2 cells has been reported before (Kreer et al., 2020), a
findingwe could confirm in our cohort. Given the increased prob-
ability of autoreactivity of near-germline antibodies, we addition-
ally investigated reactivity of SARS-CoV-2 mAbs with unfixed
murine tissue, allowing detection of reactivity to potential self-
antigens in their natural conformation. Indeed, we found that a
fraction of SARS-CoV-2-neutralizing antibodies also bound to
brain-, lung-, heart-, kidney-, or gut-expressed epitopes. Such
reactivity with host antigens should ideally be prevented by
immunological tolerance mechanisms, but complete exclusion
of such antibodies would generate ‘‘holes’’ in the antibodyCell 183, 1058–1069, November 12, 2020 1063
Figure 5. Prophylactic and Therapeutic Application of
mAb CV07-209 in a COVID-19 Hamster Model
(A) Schematic overview of the animal experiment.
(B) Body weight of hamsters after virus challenge and pro-
phylactic (pink) or therapeutic (blue) application of the SARS-
CoV-2-neutralizing mAb CV07-209 or control antibody (mean
± SEM from 9 animals per group from days 1 to 3, n = 6 from
days 4–5; n = 3 from days 6–13; mixed-effects model with post
hoc Dunnett’s multiple tests in comparison with the control
group; significance levels are shown as *p < 0.05, **p < 0.01,
***p < 0.001, and ****p < 0.0001 or not shown when not
significant.
(C and D) Left: quantification of plaque-forming units (PFU)
from lung homogenates. Right: quantification of genomic
SARS-CoV-2 RNA (gRNA) as copies per 105 cellular tran-
scripts (left y axis, filled circles) and cycle threshold (ct) of
subgenomic SARS-CoV-2 RNA (sgRNA) detection (right y axis,
unfilled circles) from samples and time points as indicated.
Values for PFUswere set to 5 when not detected, gRNA copies
below 1 were set to 1, and the ct of sgRNA was set to 46 when
not detected. Bars indicate the mean. Dotted lines represent
the detection threshold.
See also Figure 6 and Table S6.
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Figure 6. Histopathological Analysis of Hamsters after SARS-CoV-2 Infection
(A) Histopathology of representative hematoxylin-and-eosin-stained, paraffin-embedded bronchi with inserted epithelium (top row) and lung parenchyma with
inserted blood vessels (bottom row) at 3 dpi. Severe suppurative bronchitis with immune cell infiltration (hash symbol) is apparent only in the control-treated
animals with necrosis of bronchial epithelial cells (diagonal arrows). Necro-suppurative interstitial pneumonia (upward arrows) with endothelialitis (downward
arrows) is prominent in control-treated animals. Scale bars, 200 mm in the bronchus overview, 50 mm in all others.
(B) Bronchitis and edema score at 3 dpi. Bars indicate the mean.
(C) Detection of viral RNA (red) using in situ hybridization of representative bronchial epithelium present only in the control group. Scale bars, 50 mm.
(D) Histopathology of representative lung sections from areas comparable with (A) at 5 dpi. Staining of bronchi of control-treated animals showed marked
bronchial hyperplasia with hyperplasia of epithelial cells (diagonal arrow) and still existing bronchitis (hash symbol), absent in all prophylactically treated and in 2/3
(legend continued on next page)
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OPEN ACCESS Articlerepertoire. In fact, HIV utilizes epitopes shared by its envelope
and mammalian self-antigens, harnessing immunological toler-
ance to impair anti-HIV antibody responses (Yang et al., 2013)
and impeding successful vaccination (Jardine et al., 2016). To
defy virus escape in HIV and, similarly, COVID-19, anergic,
strongly self-reactive B cells likely enter germinal centers and un-
dergo clonal redemption to mutate away from self-reactivity
while retaining HIV or SARS-CoV-2 binding (Reed et al., 2016).
Interestingly, longitudinal analysis of mAbs in COVID-19 showed
that the number of SHMs in SARS-CoV-2-neutralizing antibodies
only increased marginally over time (Kreer et al., 2020). This
finding suggests that the self-reactivity observed in this study
may not be limited to mAbs of the early humoral immune
response in SARS-CoV-2 infection. Whether self-reactive anti-
bodies could contribute to extra-pulmonary symptoms in
COVID-19 awaits further studies and should be closely moni-
tored in vaccination trials.
Finally, we evaluated in detail the in vivo efficacy of the most
potent neutralizing antibody, CV07-209, in a Syrian hamster
model of SARS-CoV-2 infection. This model is characterized
by a severe phenotype including weight loss and distinct lung
pathology. Our results demonstrated that prophylaxis and treat-
ment with a single dose of CV07-209 not only led to clinical
improvement, as shown by the absence of weight loss, but
also to markedly reduced lung pathology. Although the findings
confirm the efficacy of prophylactic mAb administration as
described by other groups in mice, hamsters, and rhesus ma-
caques (Cao et al., 2020; Liu et al., 2020; Rogers et al., 2020;
Zost et al., 2020), our work also demonstrates the efficacy of
post-exposure treatment in hamsters leading to virus clearance,
clinical remission, and prevention of lung injury. We provide
detailed insights into the lung pathology of SARS-CoV-2-in-
fected hamsters at multiple times during the disease course,
including the regeneration phase. It complements two very
recent demonstrations of a therapeutic effect of mAbs in a ham-
ster model of COVID-19 (Baum et al., 2020; Li et al., 2020). These
data expand the growing knowledge about post-exposure treat-
ment from transgenic hACE2mice (Cao et al., 2020) and amouse
model using adenovector delivery of human ACE2 before virus
challenge (Liu et al., 2020). Collectively, our results indicate
that mAb treatment can be fine-tuned for exclusion of self-reac-
tivity with mammalian tissues and that mAb administration can
also be efficacious after infection, which will be the prevailing
setting in COVID-19 patients.
Limitations of Study
Although our study confirms the potential of therapeutic mAb
application for treatment of COVID-19, interpretation of the
data is limited to a first exploration of a short window between
infection and antibody administration. Although our paradigmtherapeutically treated animals (top row). Lung parenchyma staining of control-tre
epithelial cell hyperplasia and endothelialitis (insets, downward arrows). Compar
mild signs of interstitial pneumonia with mild type II alveolar epithelial cell hyperp
heterogeneous picture, with 1/3 animals showing no signs of lung pathology, 1
showing moderate multifocal interstitial pneumonia. Scale bars, 200 mm in the b
(E) Bronchitis and edema score at 5 dpi. Bars indicate the mean.
See also Figure 5 and Table S6.
1066 Cell 183, 1058–1069, November 12, 2020mimics the relevant scenario of immediate post-exposure treat-
ment, we cannot conclude whether the therapeutic benefit can
also be translated into the more common clinical setting of treat-
ment at heterogenous time points after symptoms have
occurred. For this, follow-up studies will have to focus on de-
layed mAb application after symptom onset.
We also describe the reactivity of SARS-CoV-2 mAbs to self-
antigens from different tissues. These findings require attention
and, simultaneously, careful interpretation and thorough investi-
gation to provide a better understanding of their functional rele-
vance beyond the observed binding. This includes identification
of non-viral target antigens, functional in vitro studies, and in vivo
models. The self-reactive mAbs identified in this study derived
from patients without severe extra-pulmonary symptoms. To
address a possible connection between self-reactive antibodies
and the diverse clinical manifestations of COVID-19, expression
and characterization of mAbs from patients with such disease
courses are needed.STAR+METHODS
Detailed methods are provided in the online version of this paper
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Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Jakob
Kreye (jakob.kreye@dzne.de).
Materials Availability
All requests for materials including antibodies, viruses, plasmids and proteins generated in this study should be directed to the Lead
Contact author. Materials will be made available under a Material Transfer Agreement (MTA) for non-commercial usage.
Data and Code Availability
X-ray coordinates and structure factors are deposited at the RCSB Protein Data Bank under accession codes PDB: 6XKQ and PDB:
6XKP. The accession number for the nucleotide sequences of the top 18 antibodies reported in this paper is GenBank: MW002770 -
MW002805The. The raw sequencing data associated with this manuscript together with the analysis using custom BASE software
have been deposited to Code Ocean (https://codeocean.com/capsule/7823731/tree/v1, https://doi.org/10.24433/CO.1724316.v1).
The software used for Ig sequence analysis is available at https://github.com/automatedSequencing/BASE. The published article
includes all data generated or analyzed during this study and are available from the corresponding author on request.
EXPERIMENTAL MODELS AND SUBJECT DETAILS
SARS-CoV-2-infected individuals and sample collection
The patients have given written informed consent and analyses were approved by the Institutional Review Board of Charité - Univer-
sitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität Berlin, and Berlin Institute of Health, Berlin.
All patients in this study were tested positive for SARS-CoV-2 infection by RT-PCR. Most patients belong to a prospective COVID-19
cohort (Kurth et al., 2020). Patient characteristics are described in Table S1.
Animal experiment approval and animal care
The animal experiment was approved by the Landesamt für Gesundheit und Soziales in Berlin, Germany (approval number 0086/20)
and performed in compliance with relevant national and international guidelines for care and humane use of animals. In vitro and
animal work was conducted under appropriate biosafety precautions in a BSL-3 facility at the Institute of Virology, Freie UniversitätCell 183, 1058–1069.e1–e11, November 12, 2020 e6
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OPEN ACCESS ArticleBerlin, Germany. Twenty-seven six-week old female andmale golden Syrian hamsters (Mesocricetus auratus; outbred hamster strain
RjHan:AURA, Janvier Labs) were kept in groups of 3 animals in enriched, individually ventilated cages. The animals had ad libitum
access to food andwater and were allowed to acclimate to these conditions for seven days prior to prophylactic treatment and infec-
tion. Cage temperatures and relative humidity were recorded daily and ranged from 22-24C and 40%–55%, respectively.
METHOD DETAILS
PBMC collection and FACS staining
Recombinant SARS-CoV-2-S1 protein produced in HEK cells (Creative Diagnostics, DAGC091) was covalently labeled using Cruz-
Fluor647 (Santa Cruz Biotechnology, sc-362620) according to the manufacturer’s instructions.
Using fluorescence-activated cell sorting we sorted viable single cells from freshly isolated peripheral blood mononuclear cells
(PBMCs as 7AAD-CD19+CD27+CD38+ antibody-secreting cells (ASCs) or SARS-CoV2-S1-enriched 7AAD-CD19+CD27+ memory
B cells (MBCs) into 96-well PCR plates. Staining was performed on ice for 25 minutes in PBS with 2% FCS using the following an-
tibodies: 7-AAD 1:400 (Thermo Fisher Scientific), CD19-BV786 1:20 (clone SJ25C1, BD Biosciences, 563326), CD27-PE 1:5 (clone
M-T271, BD Biosciences, 555441), CD38-FITC 1:5 (clone HIT2, BD Biosciences, 560982), and SARS-CoV-S1-CF647 at 1 mg/ml for
patients CV07, CV38, CV23, CV24, CV 38, CV48, CV-X1, CV-X2 and CV01 (second time point, fig. S1). The first patients (CV01 (first
time point), CV03, and CV05) were stained with a divergent set of antibodies: CD19-PE 1:50 (clone HIB19, BioLegend, 302207),
CD38-PEcy7 1:50 (clone HIT2, BioLegend, 303505), CD27-APC 1:50 (clone O323, BioLegend, 302809) and DAPI as viability dye.
Generation of recombinant human monoclonal antibodies
Monoclonal antibodies were generated following established protocols (Kornau et al., 2020; Kreye et al., 2016; Tiller et al., 2008) with
modifications as mentioned. We used a nested PCR strategy to amplify variable domains of immunoglobulin heavy and light chain
genes from single cell cDNA and analyzed sequences with aBASE module of customized Brain Antibody Sequence Evaluation
(BASE) software (Reincke et al., 2020). Pairs of functional Ig genes were PCR-amplified using specific primers with Q5 Polymerase
(NEB). PCR-product and linearized vector were assembled using Gibson cloning with HiFi DNA Assembly Master Mix (NEB). Cloning
was considered successful when sequence identify > 99.5% was given, verified by the cBASE module of BASE software. For mAb
expression, human embryonic kidney cells (HEK293T) were transiently transfected with matching Ig heavy and light chains. Three
days later mAb containing cell culture supernatant was harvested. Ig concentrations were determined and used for reactivity and
neutralization screening, if Ig concentration was above 1 mg/ml. For biophysical characterization assays and in vivo experiments, su-
pernatants were purified using Protein G Sepharose beads (GE Healthcare), dialyzed against PBS and sterile-filtered using 0.2 mm
filter units (GE Healthcare). For in vivo experiments, mAbs were concentrated using Pierce 3K Protein Concentrator PES (Thermo
Scientific).
SARS-CoV-2-S1 ELISA
Screening for SARS-CoV-2-specific mAbs was done by using anti-SARS-CoV-2-S1 IgG ELISAs (EUROIMMUNMedizinische Labor-
diagnostika AG) according to the manufacturer’s protocol. mAb containing cell culture supernatants were pre-diluted 1:5, patient
sera 1:100. Optical density (OD) ratios were calculated by dividing the OD at 450 nm by the OD of the calibrator included in the
kit. OD ratios of 0.5 were considered reactive.
RBD ELISA
Binding to the receptor-binding domain (RBD) of S1 was tested in an ELISA. To this end, a fusion protein (RBD-Fc) of the signal pep-
tide of the NMDA receptor subunit GluN1, the RBD-SD1 part of SARS-CoV2-S1 (amino acids 319-591) and the constant region of
rabbit IgG1 heavy chain (Fc) was expressed in HEK293T cells and immobilized onto 96-well plates from cell culture supernatant
via anti-rabbit IgG (Dianova, 711-005-152) antibodies. Then, human mAbs were applied and detected using horseradish peroxidase
(HRP)-conjugated anti-human IgG (Dianova, 709-035-149) and the HRP substrate 1-step Ultra TMB (Thermo Fisher Scientific,
Waltham, MA). All S1+ mAbs were screened at a human IgG concentration of 10 ng/ml to detect strong RBD binders and the
ones negative at this concentration were re-evaluated for RBD reactivity using a 1:5 dilution of the cell culture supernatants. To
test for specificity within the coronavirus family, we expressed and immobilized Fc fusion proteins of the RBD-SD1 regions of
SARS-CoV, MERS-CoV and the endemic human coronaviruses HCoV-229E, HCoV-NL63, HCoV-HKU1, and HCoV-OC43 and
applied mAbs at 1 mg/ml. The presence of immobilized antigens was confirmed by incubation with HRP-conjugated anti-rabbit
IgG (Dianova, 711-036-152). Assays for concentration-dependent RBD binding (Figure 1E) were developed using 1-step Slow
TMB (Thermo Fisher Scientific). EC50 was determined from non-linear regression models using Graph Pad Prism 8.
To evaluate the ability of mAbs to interfere with the binding of ACE2 to SARS-CoV-2 RBD, we expressed ACE2-HA, a fusion protein
of the extracellular region of human ACE2 (amino acids 1-615) followed by a His-tag and a hemagglutinin (HA)-tag in HEK293T cells
and applied it in a modified RBD ELISA. Captured RBD-Fc was incubated with mAbs at 0.5 mg/ml for 15 minutes and subsequently
with ACE2-HA-containing cell culture supernatant for 1 h. ACE2-HA binding was detected using anti-HA antibody HA.11 (clone
16B12, BioLegend, San Diego, CA, 901515), HRP-conjugated anti-mouse IgG (Dianova, 715-035-150) and 1-step UltraTMB.e7 Cell 183, 1058–1069.e1–e11, November 12, 2020
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ing EZ-Link Sulfo-NHS-Biotin (Thermo Fisher) according to the manufacturer’s instructions. Briefly, 50-200 mg of purified antibody
were incubated with 200-fold molar excess Sulfo-NHS-Biotin for 30 minutes at room temperature. Excess Sulfo-NHS-Biotin was
removed by dialysis for 16 hours. Recovery rate of IgG ranged from 60%–100%. RBD-Fc captured on ELISA plates was incubated
withmAbs at 10 mg/ml for 15minutes. Then, one volume of biotinylatedmcAbs at 100 ng/ml was added and themixture incubated for
additional 15 minutes, followed by detection using HRP-conjugated streptavidin (Roche Diagnostics) and 1-step Ultra TMB. Back-
ground by the HRP-conjugated detection antibodies alone was subtracted from all absorbance values.
Circos plot of public clonotypes
Antibodies which share same V and J gene on both Ig heavy and light chain are considered to be one clonotype. Such clonotypes are
considered public if they are identified in different patients. After identification of public clonotypes, they were plotted in a Circos plot
using the R package circlize (Gu et al., 2014).
Identification of 18 strongly neutralizing antibodies
To identify the most potent SARS-CoV-2 neutralizing mAb, all 122 S1-reactive mAbs were screened for binding to RBD. 87 were
defined as strongly binding to RBD (defined as detectable binding at 10 ng/ml in an RBD ELISA) and then assessed for neutralization
of authentic SARS-CoV-2 at 25 and 250 ng/ml usingmAb-containing cell culture supernatants. Antibodies were further selected (i) as
the strongest neutralizing mAb of the respective donor and / or (ii) with an estimated IC50 of 25 ng/ml or below and / or (iii) with an
estimated IC90 of 250 ng/ml or below. These were defined as the 18 most potent antibodies (top 18) and expressed as purified an-
tibodies for detailed biophysical characterization.
Surface plasmon resonance measurements
The antigen (SARS-CoV-2 S protein-RBD-mFc, Accrobiosystems) was reversibly immobilized on a C1 sensor chip via anti-mouse
IgG. Purified mAbs were injected at different concentrations in a buffer consisting of 10 mM HEPES pH 7.4, 150 mM NaCl, 3 mM
EDTA, 0.05% Tween 20. CV-X1-126 and CV38-139 were analyzed in a buffer containing 400 mM NaCl as there was a slight upward
drift at the beginning of the dissociation phase due to non-specific binding of to the reference flow.Multi-cycle-kinetics analyseswere
performed in duplicates except for non-neutralizing CV03-191. Ka, Kd and KD-values were determined using a monovalent analyte
model. Recordings were performed on a Biacore T200 instrument at 25C.
Plaque reduction neutralization test
To detect neutralizing activity of SARS-CoV-2-specific mAbs, plaque reduction neutralization tests (PRNT) were done as described
before (Wölfel et al., 2020). Briefly, Vero E6 cells (1.6 x105 cells/well) were seeded in 24-well plates and incubated overnight. For each
dilution step, mAbs were diluted in OptiPro and mixed 1:1 with 200 mL virus (Munich isolate 984) (Wölfel et al., 2020) solution con-
taining 100 plaque forming units. The 400 mL mAb-virus solution was vortexed gently and incubated at 37C for 1 hour. Each 24-
well was incubated with 200 mL mAb-virus solution. After 1 hour at 37, the supernatants were discarded and cells were washed
once with PBS and supplemented with 1.2% Avicel solution in DMEM. After 3 days at 37C, the supernatants were removed and
the 24-well plates were fixed and inactivated using a 6% formaldehyde/PBS solution and stained with crystal violet. All dilutions
were tested in duplicates. For PRNT-screening mAb dilutions of 25 and 250 ng of IgG/ml were assessed. IC50 was determined
from non-linear regression models using Graph Pad Prism 8.
Immunocytochemistry
Recombinant spike protein-based immunofluorescence assays were done as previously described (Buchholz et al., 2013; Corman
et al., 2020; Wölfel et al., 2020). Briefly, VeroB4 cells were transfected with previously described pCG1 plasmids encoding SARS-
CoV-2, MERS-CoV, HCoV-NL63,229E, -OC43, and -HKU1 spike proteins (Buchholz et al., 2013; Hoffmann et al., 2020). For trans-
fection, Fugene HD (Roche) was used in a Fugene to DNA ratio of 3:1. After 24 hours, transfected as well as untransfected VeroB4
cells were harvested and resuspended in DMEM/10% FCS to achieve a cell density of 2.5x105 cells/ml each. Transfected and un-
transfected VeroB4 cells were mixed 1:1 and 50 mL of the cell suspension was applied to each incubation field of a multitest cover
slide (Dunn Labortechnik). The multitest cover slides were incubated for 6 hours before they were washed with PBS and fixed with
ice-cold acetone/methanol (ratio 1:1) for 10 minutes. For the immunofluorescence test, the incubation fields were blocked with 5%
non-fat dry milk in PBS/0.2% Tween for 60 minutes. Purified mAbs were diluted in EUROIMMUN sample buffer to a concentration of
5 mg/ml and 30 mL of the dilution was applied per incubation field. After 1 hour at room temperature, cover slides were washed 3 times
for 5 minutes with PBS/0.2% Tween. Secondary detection was done using a 1:200 dilution of a goat-anti human IgG-Alexa488 (Dia-
nova). After 30 minutes at room temperature, slides were washed 3 times for 5 minutes and rinsed with water. Slides were mounted
using DAPI prolonged mounting medium (FisherScientific).
Crystal structure determination of Fab-RBD complexes
The coding sequence for receptor binding domain (RBD; residues 319-541) of the SARS-CoV-2 spike (S) protein was synthesized
and cloned into a customized pFastBac vector (Ekiert et al., 2011), which is designed to fuse an N-terminal gp67 signal peptideCell 183, 1058–1069.e1–e11, November 12, 2020 e8
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sequencing-confirmed pFastBac construct using the Bac-to-Bac system (Life Technologies). Baculovirus was generated by trans-
fecting purified bacmid DNA into Sf9 cells using FuGENEHD (Promega), and subsequently used to infect suspension cultures of High
Five cells (Life Technologies) at amultiplicity of infection (MOI) of 5 to 10. Infected High Five cells were incubated at 28 Cwith shaking
at 110 rpm for 72 hours for protein expression. RBD protein that was secreted into the supernatant was then concentrated using a
10 kDa MW cutoff Centramate cassette (Pall Corporation). The RBD protein in the concentrate was purified by affinity chromatog-
raphy using Ni-NTA resin (QIAGEN), followed by size exclusion chromatography on a HiLoad Superdex 200 pg column (GE Health-
care), and buffer exchanged into 20 mM Tris-HCl pH 7.4 and 150 mM NaCl using the same protocol as before (Yuan et al., 2020b).
Fabswere expressed in ExpiCHO cells and purified using affinity and size exclusion chromatography. Residues in the elbow region of
CV07-250 (112SSASTKG118) were mutated to 112FNQIKP117 to reduce elbow flexibility and facilitate crystal packing (Bailey et al.,
2018). The Fab/RBD complexes were formed by mixing the two components in an equimolar ratio and incubating overnight at
4C before setting-up crystal trials. The Fab/RBD complexes were screened for crystallization using 384 conditions of the JCSG
Core Suite (QIAGEN) on our robotic CrystalMation system (Rigaku) at The Scripps Research Institute. Crystallization trials were
set up for SARS-CoV-2 RBD in complex with a number of Fabs from this study, including CV07-250, CV07-270, CV07-283,
CV07-287, CV07-209, CV07-222, CV07-262, CV38-113, and CV38-183, but only CV07-250/RBD and CV07-270/RBD produced
diffraction quality crystals in complex with the SARS-CoV-2 RBD. CV07-250 and CV07-270 Fabs were expressed in ExpiCHO cells
and purified using affinity and size exclusion chromatography. The Fab/RBD complexes were formed bymixing the two components
in an equimolar ratio and incubating overnight at 4C before setting-up crystal trials. The complexes of CV07-250/RBD and CV07-
270/RBD were screened for crystallization at 20.0 and 12.0 mg/ml, respectively, using 384 conditions of the JCSG Core Suite
(QIAGEN) on our robotic CrystalMation system (Rigaku) at The Scripps Research Institute. Crystals appeared after day 3, were har-
vested after day 7, and then flash-cooled in liquid nitrogen for X-ray diffraction experiments. Diffraction data were collected at cryo-
genic temperature (100 K) at Stanford Synchrotron Radiation Lightsource (SSRL) on the newly constructed Scripps/Stanford beam-
line 12-1 with a beamwavelength of 0.97946 Å and processed with HKL3000 (Minor et al., 2006). Diffraction data were collected from
crystals grown in conditions: 0.085 M HEPES pH 7.5, 10% (v/v) ethylene glycol, 15% (v/v) glycerol, 8.5% (v/v) 2-propanol, 17% (w/v)
polyethylene glycol 4000 for the CV07-250/RBD complex and 0.1 M sodium cacodylate pH 6.5, 0.2 M sodium chloride, 2 M ammo-
nium sulfate, 15% (v/v) ethylene glycol for the CV07-270/RBD complex. The X-ray structures were solved by molecular replacement
(MR) using PHASER (McCoy et al., 2007) with MR models for the RBD and CV07-270 Fab from PDB 6W41 (Yuan et al., 2020b) and
4FQH, respectively. The MR model for CV07-250 Fab was generated using Repertoire Builder (Schritt et al., 2019). Iterative model
building and refinement were carried out in COOT (Emsley and Cowtan, 2004) and PHENIX (Adams et al., 2010), respectively. In the
CV07-250 + RBD structure, residues 319-337, 357- 366, 371-374, 383- 396, 516-541 were not modeled due to paucity of electron
density. The N and C-terminal regions are normally disordered in the SARS CoV-2 RBD structures. These flexible regions are not
involved in any other contacts, including crystal lattice contacts, and are on the opposite side of the RBD to the epitope, which is
well ordered. In the CV07-270 + RBD structure, Fab residues in a region of the heavy-chain constant domain also have greater
mobility as commonly found in Fabs. Likewise, the N and C-terminal residues of 319-333 and 528-541 in both RBD molecules of
the asymmetric unit are disordered. Epitope and paratope residues, as well as their interactions, were identified by accessing PDBe-
PISA (Krissinel and Henrick, 2007) at the European Bioinformatics Institute (https://www.ebi.ac.uk/pdbe/prot_int/pistart.html).
Murine tissue reactivity screening
Preparations of brain, lung, heart, liver, kidney and gut from 8-12 weeks old C57BL/6J mice were frozen in 50C 2-methylbutane,
cut on a cryostat in 20 mm sections and mounted on glass slides. For tissue reactivity screening according to established protocols
(Kreye et al., 2016), thawed unfixed tissue slices were rinsed with PBS then blocked with blocking solution (PBS supplemented with
2%Bovine Serum Albumin (Roth) and 5%Normal Goat Serum (Abcam)) for 1 hour at room temperature before incubation of mAbs at
5 mg/ml overnight at 4C. After three PBS washing steps, goat anti-human IgG-Alexa Fluor 488 (Dianova, 109-545-003) diluted in
blocking solution was applied for 2 hours at room temperature before additional three washes and mounting using DAPI-containing
Fluoroshield. Staining was examined under an inverted fluorescence microscope (Olympus CKX41, Leica DMI6000) or confocal de-
vice (Leica TCS SL). For co-staining, tissue was processed as above, but sections were fixed with 4% PFA in PBS for 10 minutes at
room temperature before blocking. For co-staining, the following antibodies were used: mouse Smooth Muscle Actin (clone 1A4,
Agilent, 172 003), goat anti-mouse IgG-Alexa Fluor 594 (Dianova, 115-585-003). For nuclei staining DRAQ5 (abcam, ab108410)
was used.
HEp2 cell assay
HEp-2 cell reactivity was investigated using the NOVA Lite HEp-2 ANA Kit (Inova Diagnostics) according to the manufacturer’s in-
structions using mAb containing culture supernatant (screening of all S1+ mAbs) or purified mAbs at 50 mg/ml (polyreactivity testing
of CV07-200, CV07-209, CV07-222, CV07-255, CV07-270 and CV38-148) and examined under an inverted fluorescence
microscope.e9 Cell 183, 1058–1069.e1–e11, November 12, 2020
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Purified mAbs were screened for reactivity against cardiolipin and beta-2 microglobulin at 50 mg/ml using routine laboratory ELISAs
kindly performed by Christian Meisel (Labor Berlin).
Hamster model of SARS-CoV-2 infection
Virus stocks for animal experiments were prepared from the previously published SARS-CoV-2 München isolate (Wölfel et al., 2020).
Viruses were propagated on Vero E6 cells (ATCC CRL-1586) in minimal essential medium (MEM; PAN Biotech) supplemented with
10% fetal bovine serum (PAN Biotech) 100 IU/ml Penicillin G and 100 mg/ml Streptomycin (Carl Roth). Stocks were stored at 80C
prior to experimental infections.
For the SARS-CoV-2 challenge experiments, hamsters were randomly distributed into three groups: In the first group (prophylaxis
group), animals received an intraperitoneal (i.p.) injection of 18mg per kg bodyweight of SARS-CoV-2 neutralizing mAb CV07-209 24
hours prior to infection. In the second and third group (treatment and control group, respectively), animals were given the identical
mAb amount two hours after infection, either with 18 mg/kg of CV07-209 (treatment group) or with 20 mg/kg of non-reactive isotype-
matched mGO53 (control group). Hamsters were infected intranasally with 1x105 PFU SARS-CoV-2 diluted in minimal essential me-
dium (MEM; PAN Biotech) to a final volume of 60 ml as previously described (Osterrieder et al., 2020).
On days 2, 5 and 13 post infection, three hamsters of each group were euthanized by exsanguination under general anesthesia
employing a protocol developed specifically for hamsters and consisting of 0.15 mg/kg medetomidine, 2 mg/kg midazolam and
2.5 mg/kg butorphanol applied as a single intramuscular injection of 200 ml (Nakamura et al., 2017). Nasal washes, tracheal swabs,
and lungs (left and right) were collected for histopathological examinations and/or virus titrations and RT-qPCR. Body weights were
recorded daily and clinical signs of all animals were monitored twice daily throughout the experiment.
Histopathology and in situ hybridization
For histopathological examination and in situ hybridization (ISH) of lung tissues, the left lung lobe was carefully removed and
immersed in fixative solution (4% formalin, pH 7.0) for 48 hours. Lungs were then embedded in paraffin and cut in 2 mm sections.
For histopathology, slides were stained with hematoxylin and eosin (HE) after dewaxing in xylene and rehydration in decreasing
ethanol concentrations. Lung sections weremicroscopically evaluated in a blinded fashion by board-certified veterinary pathologists
to assess the character and severity of pathologic lesions using lung-specific inflammation scoring parameters (Dietert et al., 2017) as
previously described for SARS-Cov2 infection in hamsters (Gruber et al., 2020; Osterrieder et al., 2020). These parameters included
severity of interstitial pneumonia, immune cell infiltration by neutrophils, macrophages, and lymphocytes, bronchitis, epithelial ne-
crosis of bronchi and alveoli, hyperplasia of bronchial epithelial cells and type II-alveolar epithelial cells, endothelialitis, perivascular
lymphocytic cuffing, as well as alveolar edema and perivascular edema (Table S6). The following parameters were evaluated to
assess three different scores: (1) the bronchitis score that includes severity of bronchial inflammation and epithelial cell necrosis
of bronchi (Figures 6B and 6E), (2) the regeneration score including hyperplasia of bronchial epithelial cells and type-II-alveolar
epithelial cells, and (3) the edema score including alveolar and perivascular edema (Figures 6B and 6E).
ISH was performed as reported previously (Erickson et al., 2020; Osterrieder et al., 2020) using the ViewRNA ISH Tissue Assay Kit
(Invitrogen by Thermo Fisher Scientific) following themanufacturer’s instructions with theminor following adjustments. Probes for the
detection of the Nucleoprotein (N) gene RNA of SARS-CoV-2 (NCBI database NC_045512.2, nucleotides 28,274 to 9,533, assay ID:
VPNKRHM), and themurine housekeeping gene eukaryotic translation elongation factor-1a (EF1a; assay ID: VB1-14428-VT, Affyme-
trix, Inc.), that shares 95% sequence identity with the Syrian hamster, were designed. Lung sections (2 mm thickness) on adhesive
glass slides were dewaxed in xylol and dehydrated in ethanol. Tissues were incubated at 95C for 10 minutes with subsequent pro-
tease digestion for 20 minutes. Sections were fixed with 4% paraformaldehyde in PBS (Alfa Aesar, Thermo Fisher) and hybridized
with the probes. Amplifier and label probe hybridizations were performed according to the manufacturer’s instructions using fast
red as the chromogen, followed by counterstaining with hematoxylin for 45 s, washing in tap water for 5 minutes, and mounting
with Roti-Mount Fluor-Care DAPI (4, 6-diaminidino-2-phenylindole; Carl Roth). An irrelevant probe for the detection of pneumolysin
was used as a control for sequence-specific binding. HE-stained and ISH slides were analyzed and images taken using a BX41 mi-
croscope (Olympus) with a DP80 Microscope Digital Camera and the cellSens Imaging Software, Version 1.18 (Olympus).
Virus titrations, RNA extractions and RT-qPCR
To determine virus titers from 25 mg lung tissue, tissue homogenates were serially diluted and titrated on Vero E6 cells in 12-well-
plates. Three days later, cells were formalin-fixed, stained with crystal violet and plaques were counted. RNA was extracted from
homogenized lungs, nasal washes and tracheal swabs using the innuPrep Virus DNA/RNA Kit (Analytik Jena) according to the man-
ufacturer’s instructions. We quantified RNA using a one-step RT qPCR reaction with the NEB Luna Universal Probe One-Step RT-
qPCR kit (New England Biolabs) by following themanufacturer’s instructions and by using previously published TaqMan primers and
probes (SARS-CoV-2 E_Sarbeco and hamster RPL18) (Corman et al., 2020; Zivcec et al., 2011) on a StepOnePlus RealTime PCR
System (Thermo Fisher Scientific). Primer concentrations were 400 nM for forward (E_Sarbeco_F; 50-ACAGGTACGTTAATAGTTAA
TAGCGT-30; RPL18_F: 50-GTTTATGAGTCGCACTAACCG-30) and reverse (E_Sarbeco_R; 50-ATATTGCAGCAGTACGCACACA-30;
RPL18_R: 50-TGTTCTCTCGGCCAGGAA-30) primers, and 200 nM for the TaqMan Probe (E_Sarbeco_P: FAM-ACACTAGCCATCCT
TACTGCGCTTCG-BBQ; RPL18_P YAK-TCTGTCCCTGTCCCGGATGATC-BBQ).Cell 183, 1058–1069.e1–e11, November 12, 2020 e10
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sequence and by oligonucleotides targeting regions within the E gene, as described previously (Corman et al., 2020; Wölfel et al.,
2020): The sgRNA RT-PCR assay used the Platinum SuperScript III RT-PCR-System with Platinum Taq DNA Polymerase (Thermo
Fisher Scientific). A 25 mL reaction contained 5 mL of RNA, 12.5 mL of 2 3 reaction buffer provided with the kit (containing 0.4 mM
of each deoxyribont triphosphates (dNTP) and 3.2 mM magnesium sulfate), 1 mL of reverse transcriptase/Taq mixture from the kit,
1 mg of nonacetylated bovine serum albumin (Roche), and 0.4 mL of a 50 mM magnesium sulfate solution (Thermo Fisher Scientific).
Primer concentrations were 400 nM for forward (F; 50-CGATCTCTTGTAGATCTGTTCTC-30) and reverse (R; 50-ATATTGCAGCAG-
TACGCACACA-30) primers, and 200 nM for the TaqMan Probe P; (FAM-ACACTAGCCATCCTTACTGCGCTTCG-BBQ). Thermal
cycling involved 10 min at 50C for reverse transcription, followed by 3 min at 95C and 45 cycles of 10 s at 95C, 15 s at 56C,
and 5 s at 72C.
QUANTIFICATION AND STATISTICAL ANALYSIS
All statistical tests were performed using GraphPad Prism, version 8.4. For comparison of SHM number (Figure S1D), a D’Agostino-
Pearson normality test showed that the number of SHM was not normally distributed, therefore a Kruskal-Wallis test was used with
posthoc Dunn’s multiple comparisons tests. For bodyweight changes from hamster experiments (Figure 5B) a D’Agostino-Pearson
normality test revealed normal distribution, Thus, statistical significance of bodyweight changes from hamster experiments was
tested using a mixed-effects model (two-way ANOVA) with posthoc Dunnett’s multiple comparisons test in comparison to control
group. Statistical details can be found in the figure legends. For top 18 mAbs, EC50 and IC50 values (Figure 1; Table S3) were deter-
mined from non-linear regression models using Graph Pad Prism 8.4. Binding kinetics of mAbs to RBD were modeled from multi-
cycle surface plasmon resonance measurements (Figure S4) using the Biacore T200 software, version 3.2.e11 Cell 183, 1058–1069.e1–e11, November 12, 2020
Supplemental Figures
Figure S1. SARS-CoV-2-S1 Serum IgG Response from COVID-19 Patients, Flow Cytometry Gating, and Characteristics of Ig Sequences,
Related to Figure 1 and Tables S1 and S2
(A) Serum IgG response determined as the normalized optical density (OD) in a SARS-CoV-2-S1 ELISA in relation to the time point of diagnosis defined by the first
positive qPCR test. Upward arrowhead denotes the appearance of first symptoms. Downward arrowhead denotes the PBMC isolation. From patient CV01,
PBMC samples were isolated at two time points as indicated by the second downward arrow with an asterisk (*).
(B-C) A representative flow cytometry plot from patient CV38 indicating gating on (B) CD19+CD27+antibody-secreting cells (ASC) and (C) SARS-CoV-2-S1-
stained memory B cells (S1-MBC). Cells were pre-gated on live CD19+ B cells.
(D) Comparison of somatic hypermutation (SHM) count within immunoglobulint V genes combined from heavy and light chains of S1-reactive (S1+, blue) and non-
S1-reactive (S1-, gray) mAbs. Statistical significance was determined using a Kruskal-Wallis test with Dunn’s multiple comparison test. (ASC: n = 20 S1+, n = 260
S1-; S1-MBC: n = 102 S1+, n = 50 S1-, n-values represent number of mAbs). All expressed mAbs are displayed. Each triangle represents one mAb, isolated from
an ASC (inverted triangle) or a S1-MBC (triangle). Bars indicate mean.
(E-F) Length comparison of complementarity-determining region (CDR) 3 amino acid sequences between S1+ and S1- mAbs within (E) heavy and (F) light chains.
Bars indicate mean. Symbols and colors have the same meaning as in (D).
(G) Frequency of RBD-binder (S1+RBD+) and non-RBD-binder (S1+RBD-) relative to all expressed mAbs (upper lanes) and relative to S1+ mAbs (lower lanes).
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Figure S2. Comparison of Variable Gene Use, Related to Figure 1 and Table S2
Comparison of gene usage between SARS-CoV-2-S1-reactive (S1+) and non-reactive (S1-) mAbs is shown for immunoglobulin (A) variable heavy (IGHV), (B)
variable kappa (IGKV) and (C) variable lambda (IGLV) genes. Bars depict percentage of gene usage of all expressed mAbs within each group.
ll
OPEN ACCESS Article
Figure S3. Clonal Expansion and Public or Common Clonotypes, Related to Figure 1 and Table S2.
(A) Pie charts represent clonal relationship of all expressed mAbs from each donor separately for antibody secreting cells (ASC) and S1-stained memory B cells
(S1-MBC). mAbs were considered S1-reactive (S1+) or non-S1-reactive (S1-) based on SARS-CoV-2-S1 ELISA measurements. Antibodies were considered to
be clonally expanded when they were isolated from multiple cells. (B) Circos plot displays all isolated mAbs from ten donors. Interconnecting lines indicate
relationship betweenmAbs that share the same V and J gene on both Ig heavy and light chain. Such public or shared clonotypes in whichmore than 50%ofmAbs
are S1-reactive are represented as colored lines. Small black angles at the outer circle border indicate expanded clones within the respective donor.
(C) Properties of public clonotypes from S1+ mAbs according to the colors used in (B) with sequence similarities between mAbs isolated from different donors,
also within CDR3.
(D) Public or common antibody response using VH3-53 and VH3-66 genes.
IGHV, IGHJ IGKV, IGKJ, IGLV, IGLJ = V (variable) and J (joining) genes of immunoglobulin heavy, kappa, lambda chains; CDR = complementarity-determining
region; n.exp. = not expressed.
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Figure S4. Binding Kinetic Measurements of mAbs to the RBD, Related to Figure 1 and Table S3
Binding kinetics of mAbs to RBD were modeled (black) from multi-cycle surface plasmon resonance (SPR) measurements (blue, purple, orange). Fitted
monovalent analyte model is shown. For CV07-200, neither a bivalent nor a monovalent analyte model described the data accurately (no model is shown). Three
out of the 18 selected mAbs for detailed characterization (top 18) were not analyzed using multi-cycle-kinetics: CV07-270 was excluded as it interacted with the
anti-mouse IgG reference surface on initial qualitative measurements. CV07-255 and CV-X2-106 were not analyzed since they showed biphasic binding kinetics
and relatively fast dissociation rates in initial qualitative measurements. Non-neutralizing CV03-191, a mAb not included in the top 18 mAbs, was included in the
multicycle experiments as it has the same clonotype as strongly neutralizing CV07-209 (Figure S4C). All measurements are performed by using a serial 2-fold
dilution of mAbs on reversibly immobilized SARS-CoV-2-S1 RBD-mFc.
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Figure S5. Binding Epitope Characterization of Selected mAbs, Related to Figures 1, 3, and 4 and Table S3
(A) Competition for RBDbinding between top 18mAbs and ACE2. ELISA-basedmeasurements of humanACE2 binding to SARS-CoV-2 RBD after pre-incubation
with the indicated neutralizing mAbs. Values are shown relative to antibody-free condition as mean + SD from three independent measurements.
(B) Competition for RBD binding between combinations of potent neutralizing mAbs is illustrated as a heatmap. Shades of green indicate the degree of
competition for RBD binding of detection mAb in presence of 100-fold excess of competing mAb relative to non-competition conditions. Green squares indicate
no competition. Values are shown as mean of two independent experiments.
(legend continued on next page)
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(C) Representative immunofluorescence staining on VeroB4 cells overexpressing spike protein of indicated coronavirus with SARS-CoV-2 mAb CV07-209 at
5 mg/ml. For all other 17 of the selected 18 mAbs (top 18, Table S3), similar results were obtained.
(D) Binding of indicated mAbs to fusion proteins containing the RBD of indicated coronaviruses and the constant region of rabbit IgG revealed by ELISA. For all
other top 18 mAbs, similar results were obtained as for CV07-209. Values indicate mean + SD from two wells of one experiment.
(E) Representative HEp-2 cell staining with a commercial anti-nuclear antibody as positive control revealed nuclear binding (top). S1-reactive non-neutralizing
mAb CV38-148 exhibited cytoplasmatic binding (middle). Neutralizing mAb CV07-209 showed no binding (bottom). All mAbs selected for detailed character-
ization (top 18, Table S3) revealed similar results like CV07-209 when used at 50 mg/ml. Representative scale bar: 25 mm.
(F) Structural comparison of CV07-270/RBD and P2B-2F6/RBD complexes. Structure of CV07-270 (pink, left) and structure of P2B-2F6 (PDB 7BWJ) (Ju et al.,
2020) (blue, middle) in complex with RBD (white), as well as superimposition of the structures of CV07-270/RBD and P2B-2F6/RBD based on the RBD (right).
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Figure S6. Comparison of Sequences of CV07-250 and CV07-270 with Their Putative Germline Sequences, Related to Figures 3 and 4
(A) Alignment of CV07-250 with the germline IGHV1-18 sequence (nucleotide SHM rate 5.8%) and IGLV2-8 (nucleotide SHM rate 5.4%).
(B) Somatic mutations VH S31H, VL G29A, VL N31H, VL Y32F, VL S34T, and VL L46V are located in the CV07-250 paratope with other somatic mutations in all of
the CDRs that may affect overall CDR conformation and interactions. Hydrogen bonds are represented by dashed lines. Distances between atoms are shown in
solid lines. CV07-250 heavy chain is in dark cyan and light chain is in light cyan. SARS-CoV-2 RBD is in light gray.
(legend continued on next page)
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(C) Alignment of CV07-270 with the germline IGHV3-11 sequence (nucleotide SHM rate 0.7%) and IGLV2-14 (nucleotide SHM rate 0%). The regions that
correspond to CDR H1, H2, H3, L1, L2, and L3 are indicated. Residues that differ from the germline are highlighted in red. Residues that interact with the RBD are
highlighted in yellow. Residue positions in the CDRs are labeled according to the Kabat numbering scheme.
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